HC Wainwright Has Negative Forecast for Precigen Q1 Earnings

Precigen, Inc. (NASDAQ:PGEN) – HC Wainwright lowered their Q1 2025 earnings per share (EPS) estimates for Precigen in a research report issued on Thursday, March 20th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will post earnings per share of ($0.08) for the quarter, down from their prior forecast of ($0.04). HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Precigen’s Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.29) EPS and FY2026 earnings at ($0.06) EPS.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.02. Precigen had a negative return on equity of 123.06% and a negative net margin of 3,521.68%. The business had revenue of $1.19 million during the quarter, compared to the consensus estimate of $1.30 million.

Separately, JMP Securities reiterated a “market outperform” rating and issued a $5.00 price target on shares of Precigen in a research note on Tuesday, January 14th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $7.00.

Precigen Stock Performance

NASDAQ PGEN opened at $1.81 on Monday. The stock has a market cap of $532.22 million, a PE ratio of -3.29 and a beta of 1.58. The firm has a 50-day moving average of $1.61 and a 200-day moving average of $1.15. Precigen has a 52-week low of $0.65 and a 52-week high of $2.17.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. ProShare Advisors LLC lifted its holdings in shares of Precigen by 26.6% during the fourth quarter. ProShare Advisors LLC now owns 51,822 shares of the biotechnology company’s stock worth $58,000 after buying an additional 10,900 shares in the last quarter. Cetera Investment Advisers raised its stake in Precigen by 8.9% in the 4th quarter. Cetera Investment Advisers now owns 283,562 shares of the biotechnology company’s stock worth $318,000 after purchasing an additional 23,250 shares in the last quarter. Cary Street Partners Financial LLC bought a new stake in Precigen in the 4th quarter valued at about $98,000. Bank of America Corp DE boosted its holdings in Precigen by 11.6% in the 4th quarter. Bank of America Corp DE now owns 207,300 shares of the biotechnology company’s stock valued at $232,000 after purchasing an additional 21,626 shares during the period. Finally, BNP Paribas Financial Markets bought a new position in shares of Precigen during the fourth quarter worth approximately $27,000. 33.51% of the stock is owned by institutional investors and hedge funds.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.